Sym004 in Metastatic Colorectal Cancer and ECD-EGFR Patients
Phase 2
Withdrawn
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- Drug: Sym004
- Registration Number
- NCT02965417
- Lead Sponsor
- Symphogen A/S
- Brief Summary
This is a single arm, phase 2, open-label, multicenter trial in patients with metastatic colorectal cancer (mCRC) and acquired resistance to anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) and documented mutation of extra cellular domain EGFR (ECD-EGFR).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- WITHDRAWN
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Read More
Exclusion Criteria
Not provided
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Sym004 Sym004 All patients will receive a loading dose of Sym004, followed by weekly (q1w) infusions
- Primary Outcome Measures
Name Time Method Best overall response (OR) assessed by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 1 year
- Secondary Outcome Measures
Name Time Method